CN118382457A - 用于治疗肛门高级鳞状上皮内病变(hsil)的组合物和方法 - Google Patents

用于治疗肛门高级鳞状上皮内病变(hsil)的组合物和方法 Download PDF

Info

Publication number
CN118382457A
CN118382457A CN202280082724.8A CN202280082724A CN118382457A CN 118382457 A CN118382457 A CN 118382457A CN 202280082724 A CN202280082724 A CN 202280082724A CN 118382457 A CN118382457 A CN 118382457A
Authority
CN
China
Prior art keywords
nucleotide sequence
seq
sequence encoding
nucleic acid
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082724.8A
Other languages
English (en)
Chinese (zh)
Inventor
严健
容·约瑟夫·金
普拉卡什·布扬
杰弗里·斯科尔尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of CN118382457A publication Critical patent/CN118382457A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280082724.8A 2021-10-22 2022-10-21 用于治疗肛门高级鳞状上皮内病变(hsil)的组合物和方法 Pending CN118382457A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163270929P 2021-10-22 2021-10-22
US63/270,929 2021-10-22
PCT/US2022/078551 WO2023070109A1 (en) 2021-10-22 2022-10-21 Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Publications (1)

Publication Number Publication Date
CN118382457A true CN118382457A (zh) 2024-07-23

Family

ID=86059748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082724.8A Pending CN118382457A (zh) 2021-10-22 2022-10-21 用于治疗肛门高级鳞状上皮内病变(hsil)的组合物和方法

Country Status (10)

Country Link
US (1) US20230233659A1 (https=)
EP (1) EP4419138A4 (https=)
JP (1) JP2024539188A (https=)
KR (1) KR20240099266A (https=)
CN (1) CN118382457A (https=)
AU (1) AU2022371672A1 (https=)
CA (1) CA3235779A1 (https=)
CO (1) CO2024006161A2 (https=)
MX (1) MX2024004878A (https=)
WO (1) WO2023070109A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58080B1 (sr) * 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) * 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
WO2018209322A1 (en) * 2017-05-11 2018-11-15 Inovio Pharmaceuticals, Inc. Clinical and immunologic biomarkers for regression of high grade cervical dysplasia and clearance of hpv16 and hpv18 infection after immunotherapy
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia

Also Published As

Publication number Publication date
US20230233659A1 (en) 2023-07-27
WO2023070109A1 (en) 2023-04-27
EP4419138A4 (en) 2026-03-04
AU2022371672A1 (en) 2024-05-16
KR20240099266A (ko) 2024-06-28
JP2024539188A (ja) 2024-10-28
EP4419138A1 (en) 2024-08-28
MX2024004878A (es) 2024-07-15
CO2024006161A2 (es) 2024-06-27
CA3235779A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US11844830B2 (en) Vaccines for human papilloma virus and methods for using the same
JP5996191B2 (ja) ヒトパピローマウイルスの改良型ワクチンおよびその使用方法
JP7765407B2 (ja) 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法
JP2026031543A (ja) 再発性呼吸器乳頭腫症のための改善されたワクチンおよびそれを使用するための方法
US20230277645A1 (en) Compositions and methods for treating vulvar dysplasia
CN118382457A (zh) 用于治疗肛门高级鳞状上皮内病变(hsil)的组合物和方法
HK40085176A (en) Improved vaccines for recurrent respiratory papillomatosis and methods for using the same
HK40070003A (en) Improved vaccines for human papilloma virus and methods for using the same
HK1164688A (en) Improved vaccines for human papilloma virus and methods for using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination